Experimental assessment of drugs synergy is more expensive than examining single agents because, compared to the number of individual compounds, the total number of possible combinations is exponentially high. Therefore, AI/ML computational approaches such as networkbased and structure-activity relationship methods can expedite identification and prioritization of synergistic combinations from large libraries of combinations. However, only a limited number of